Man Group
STML

Man Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Man Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-453,108
Closed -$5.82M – 2086
2019
Q1 		$5.82M Buy
+453,108
New +$5.12M 0.02% 834

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Man Group's STML Position: Q2 2019 in Review

Man Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 453,108 shares — an estimated $5.82M sold.

Man Group first reported a position in STML in Q1 2019 and held it in 1 quarter. The position peaked at $5.82M in Q1 2019. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

  • Man Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Man Group sold 453,108 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $5.82M.
  • Man Group first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Man Group's Stemline Therapeutics, Inc. position peaked at $5.82M in Q1 2019.
  • 96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Man Group's 13F filing for Q2 2019, filed 14 Aug 2019.